Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Molecular Partners AGNASDAQ: MOLN

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of CHF 936K fell 18.0% year over year, behind the -4.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.8% from the prior quarter. Over 3 fiscal years it compounded at -4.6% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -18.0% toward the trailing-twelve-month pace of -4.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 936K-3.8% QoQ
Last fiscal yearDec 2025
CHF 4.42M+7.6% YoY
LTMMar 2026
CHF 4.21M-4.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.0%——
1 year+7.6%——
3-year CAGR-4.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CHF · from the cash flow

Latest · FY2025
4.42M CHF
Year-over-year change
+7.6%
4-year CAGR
+2.0%

Stock-Based Compensation vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4.1% is the 4th highest of 9, against a peer median of -13.8%.
  • Over three fiscal years its annual growth of -4.6% compares with a peer median of -1.5%.
MOLN Competitors
Stock-Based Compensation for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$21.22M USD-43.4%-16.7%115.2%
PEPGPepGen Inc.LTM Mar 2026$10.03M USD-22.0%+30.6%—
NKTXNkarta, Inc.LTM Mar 2026$7.62M USD-49.8%-20.2%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$6.67M USD-45.2%-9.2%210.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.49M USD-5.6%+3.2%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$6.14M USD+9.4%-6.2%344.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.99M USD+19.7%+10.2%1140.6%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$3.05M USD+83.8%+67.0%—
Peer median (excluding MOLN) —-13.8%-1.5%277.3%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
Deferred Income Tax2K002K2K
Stock-Based Compensation4.09M5.09M5.21M4.11M4.42M
Change in Working Capital(34.67M)(6.01M)(6.01M)(3.8M)1.16M
Accounts Receivables(23.37M)25.26M(933K)(347K)463.2K
Inventory21.72M(19.93M)000
Accounts Payables1.66M(5.34M)(812K)524K62.08K
Other Working Capital(34.67M)(6.01M)(4.27M)(3.97M)630.33K
Other Non-Cash Items848K(753K)1.36M(7.88M)2.67M
Operating Cash Flow(90.95M)118.57M(59.01M)(59.25M)(51.26M)
Capital Expenditures(1.31M)(1.42M)(575K)(723K)(714K)
Acquisitions (Net)374K0000
Purchases of Investments(88.88M)(299.42M)(277.83M)(240.05M)(66.28M)
Sales of Investments67.88M199.22M319.44M277.02M137.81M
Other Investing Activities(304K)494K3.83M4.22M1.73M
Investing Cash Flow(22.24M)(101.12M)44.64M40.49M72.55M
Debt Repayment(1.18M)(1.19M)(1.2M)(1.21M)(1.21M)
Common Stock Issued51.49M250K31K17.34M63K
Common Stock Repurchased0(631K)000
Dividends Paid00000
Other Financing Activities267K250K31K(1.7M)0
Financing Cash Flow50.58M(1.57M)(1.17M)14.43M(1.15M)
Effect of Forex Changes701K258K(5.1M)894K(1.36M)
Net Change in Cash(61.91M)16.13M(20.64M)(3.44M)18.78M
Free Cash Flow(92.26M)117.15M(59.81M)(59.97M)(51.97M)

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.